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(P  0.05). In addition, patients’ race and gender do not affect the medication adher-
ence (P  0.10) and, patients’ years of education, BMI and age are positively associated 
with adherence (P  0.05). CONCLUSIONS: In recent years, one out of three people 
in U.S. had at least one gap in insurance coverage due to job change or temporary 
unemployment in the United States. Studies focusing on the current insurance status 
may underestimate the impact of health insurance gaps and the population at risk.
The policy debates on health insurance should not only focus on the uninsured but
also those affected by intermittent non-coverage. Further research is needed on 
how insurance instability may affect treatment of other chronic conditions other than
hypertension.
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OBJECTIVES: Aliskiren is the ﬁ rst marketed direct renin inhibitor approved for
the treatment of hypertension in 2007. Study objectives were to evaluate the utilization 
and persistence of aliskiren in a real-world setting. METHODS: A retrospective cohort 
analysis was conducted using data from a large US pharmacy beneﬁ t manager who 
administers beneﬁ ts to 27 million members nationally. Patients 18 years or older
with at least two claims for aliskiren within a 12 month period of initiating treat-
ment between April 2007 and October 2007 were included in the analysis. Patients
also were required to be continuously enrolled in the same health plan 12 months 
prior to and 13 months after initiating aliskiren. Persistence on aliskiren, deﬁ ned 
as time to discontinuation (i.e., 30 day medication gap), was evaluated using a 
multivariate Cox proportional hazards model. Co-variates adjusted in the model
included age, sex, comorbidities, geographical region, insurance type, copay, pre-
scriber specialty and prior antihypertensive utilization. RESULTS: A total of 1329 
patients were identiﬁ ed as having received aliskiren. Mean patient age was 63.5 (s.d. 
 13) years and 52.3% were female. Most patients receiving aliskiren were not
naïve to antihypertensive treatment. In the 12 months prior to initiating aliskiren, 
90.1% of patients had received at least one other antihypertensive medication, and
57.3% had used 3 or more classes of antihypertensives. Mean persistence on 
aliskiren was 248 (s.d.  132) days. Multivariate analysis of persistence on aliskiren 
suggest that the risk of discontinuing was higher among those with copays q$50 
relative to copays between $0 and $5 (Hazard ratio:1.74, 95% CI: 1.34–2.34).
CONCLUSIONS: Aliskiren is most used among patients previously treated with other
antihypertensives and a lower pharmacy copay was an important factor associated 
with medication persistence. Additional research is needed to assess clinical implica-
tions of persistence.
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THE IMPACT OF MEDICARE PART D ON ELDERLY PATIENTS’
COMPLIANCE WITH STATINS
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OBJECTIVES: To investigate the impact of Medicare Part D on elderly patients’
compliance with statins. METHODS: This is a quasi-experimental study with a
pre-test and post-test for a treatment and comparison group. This study used IMS 
Health’s LifeLink longitudinal patient level data. The subjects were elderly patients 
who ﬁ lled prescriptions for statins in both January 2005 and January 2006. The sub-
jects who enrolled in Medicare Part D in 2006 served as the treatment group and 
those who did not enroll served as the comparison group. Compliance was measured
by proportion of days covered (PDC) over 11 months in both 2005 (pre-test) and
2006 (post-test). The subjects’ baseline characteristics including age, gender, payment
type, and patient type (statin naive vs. continuing) were compared by t-test or chi-
square test. The difference-in-difference model was used to test whether Medicare
Part D has an impact on patients’ compliance. RESULTS: A total of 473,475 elderly
patients ﬁ lled statin prescriptions in both January 2005 and January 2006. The mean 
age was 71.6 years with 55.85% female. A majority of the subjects was continuing
statin users in 2005 (97.52%) and had pharmacy insurance (97.98%). A total of 
201,378 (42.53%) patients enrolled in Medicare Part D in 2006. Female patients
(chi-square  6101.43, p  0.0001) and patients who paid their prescriptions by cash
in 2005 (chi-square  2264.82, p  0.0001) were more likely to enroll Medicare Part
D in 2006. The average PDC was 80.33% and 74.40% for Medicare Part D patients
and 80.04% and 71.80% for non-Medicare Part D patients in 2005 and 2006,
respectively. After controlling baseline characteristics, Medicare Part D patients had
2.31% more PDC than non-Medicare Part D patients (b  2.31, t  23.69, p  0.0001). 
CONCLUSIONS: Medicare Part D has a signiﬁ cant and positive impact on elderly
patients’ medication compliance. It is important to encourage elderly patients to enroll
Medicare Part D.
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OBJECTIVES: To assess quality of care in selected California Medicaid(Medi-Cal)
diseases through evaluation of adherence to clinical practice guidelines(CPG) and
medications. METHODS: Eligibility and claims data (2002–2004) were used to 
identify patients with hyperlipidemia(HYPL), hypertension(HYPT), coronary artery 
disease(CAD), congestive heart failure(CHF), diabetes(DIAB), or depression(DEP). 
Adherence was assessed using 2004 data. CPG adherence was based on appropriate 
medication use and adherence to recommended laboratory tests(HbA1c,LDL-C) and 
eye examinations for diabetes patients. Nonadherence to medications was based on 
medication possession ratio 0.8. Chi-square tests were conducted to evaluate the 
association of CPG and medication nonadherence with demographic variables. 
RESULTS: The proportion of patients not using appropriate medications varied by 
disease(62% DEP, 43% HYPT, 40% HYPL, 31% CAD, 25% for both DIAB and 
CHF). Approximately 74% of CHF patients were not using any beta blocker(BB).
Younger age (65 years;p  0.01), Blacks(vs. Whites;p  0.0001), and Medicaid-only 
patients(vs. Medicare/Medicaid dually eligible;p  0.0001,non signiﬁ cant for BB) were 
more likely to lack appropriate medications, with the exception of depression, where
older patients and whites were more likely without appropriate medications(all p 
0.0001). For diabetes patients, 90% lacked HbA1c test, 84% lacked LDL-C test, and
57% were without an eye exam. Older and dually eligible patients were less adherent
with these measures (all p  0.0001). Nonadherence with medications was high (84%
DEP, 72% CHF, 69% HYPT, 51% CAD, 48% HYPL, 41% DIAB), with younger 
age(p  0.05), Blacks(p  0.0001), and Medicaid-only patients(p  0.0001, non sig-
niﬁ cant for BB) more likely nonadherent than comparison subgroups. CONCLU-
SIONS: Medi-Cal adherence to CPG and medications varied by condition, but was 
suboptimal across all diseases. A greater proportion of patients were nonadherent to 
medication than were not using appropriate medications. Future investigation focused
on potential factors inﬂ uencing medication nonadherence(i.e.,poor disease knowledge, 
cultural beliefs) is recommended. Disease-management programs designed for speciﬁ c 
diseases, and addressing patient-related characteristics (age, race) along with alterable
factors(eligibility), may be most effective for improving adherence.
PODIUM SESSION III: DIABETES – Outcomes Research &
Health Care Policy Studies
DB1
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OBJECTIVES: Type 2 diabetes is a chronic illness that affects more than 17 million 
Americans, leading to early death as well as to reduced quality of life due to com-
plications such as blindness, renal failure etc. This study was undertaken with the
aim of estimating cost-effectiveness of the premix analog insulin, biphasic insulin
aspart 30 (BIAsp), when switched from biphasic human insulin (BHI). METHODS:
The well validated CORE Diabetes Model was used to project the clinical outcomes 
based on short-term data (26 weeks) from a Canadian subset of the IMPROVE™ 
observational study. The cohort (n  310) had a mean age of 64.2 o 10.96 years 
and 61.7% are male. In the IMRPOVE™ study, patients were switched from BHI 
to BIAsp and the main results included a reduction of HbA1c from 8.42 o 1.61% 
to 7.84 o 1.46%, an increase in BMI of 0.28 o 2.33 kg/m2 and a reduction in major
and minor hypoglycemic events by 75% and 33%, respectively. Total direct medical
costs (complications  treatment costs) were projected, using US unit costs, over
patient lifetimes, and future costs and clinical beneﬁ ts discounted at 3% per annum. 
RESULTS: The short-term beneﬁ ts of switching from BHI to BIasp are projected to
lead to an increase in discounted quality-adjusted life expectancy of 0.276 years (4.289
o 0.094 versus 4.013 o 0.098). Increased total lifetime costs/patient is $4,936 ($84,776
o 2,423 versus $79,840 o 2,545) with BIasp. Combining costs and clinical outcomes 
result in an incremental cost-effectiveness ratio of $17,859 per quality-adjusted life 
year (QALYs) gained. CONCLUSIONS: Higher acquisition costs of BIasp are pro-
jected to be partly offset by reduced later diabetes-related complications. The net life 
time cost increase is greatly justiﬁ ed by improved outcomes. The incremental cost-
effectiveness ratio is well within what is normally considered good value for money 
in the United States.
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OBJECTIVES: Anti-hypertensive therapy (AHT), especially the drug classes acting on 
Renin-Angiotensin system (RAS) and Calcium Channel Blockers (CCB), is known to 
delay the onset of dementia. The aim of this study was to determine whether different 
AHT drug classes are independent risk factors for dementia in DM patients, who are
at increased risk of dementia. METHODS: For the purpose of this retrospective study, 
we identiﬁ ed a national cohort of US veterans (age q 65 years) with incident DM
between October 1996 and December, 2000 in the VA records or between January,
1999 and December, 2000 in the VA-Medicare merged data. The presence of hyperten-
sion (HT) was also assessed within the same period. The period prevalence for each 
